StockData
Tyra Biosciences, Inc. logo

Tyra Biosciences, Inc. (TYRA) company profile

TYRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$19.57−0.17 (-0.86%)

Close on Nov 17, 2026Market cap $1.17BP/E –Yield –

About Tyra Biosciences

Pharmaceutical Preparations, SIC 2834

Tyra Biosciences, Inc. is a clinical-stage biotechnology company developing targeted small molecule therapies focused on Fibroblast Growth Factor Receptor (FGFR) biology. The company utilizes its proprietary SNÅP drug design platform, combining protein crystallography, cell-based assays, and animal models to discover therapies for oncology and rare genetically defined conditions. Its product pipeline includes oral dabogratinib, an FGFR3-selective candidate evaluated for low-grade upper tract urothelial carcinoma, intermediate-risk non-muscle invasive bladder cancer, and achondroplasia. Other pipeline candidates include TYRA-430 for FGF19-positive hepatocellular carcinoma and TYRA-200 for FGFR2-altered intrahepatic cholangiocarcinoma.

The company operates in the biotechnology sector and conducts research and development activities in the United States. Its operations span clinical evaluation of its drug candidates across multiple research sites and patient cohorts globally. Tyra Biosciences maintains its principal executive offices in Carlsbad, California.

Summary of the business section of Tyra Biosciences's latest annual report, written by StockData.

Company profile

Company

Legal name
Tyra Biosciences, Inc.
Headquarters
Carlsbad, CA
Address
2656 State Street 92008
Phone
(619) 728-4760
Website
tyra.bio
Employees
87, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, San Diego, California

Stock & identifiers

Ticker
TYRA
Exchange
Nasdaq
IPO date
Sep 15, 2021
Shares outstanding
60M, Jul 31, 2026
Public float
$297.30M, Jun 30, 2025
Filer category
<br>Emerging growth company
SEC CIK
1863127
CUSIP
90240B106
ISIN
US90240B1061
FIGI
BBG00RCQD9D1
Share class FIGI
BBG00RCQD9F9
EIN
83-1476348

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Todd HarrisPresident and CEO, Director1,438,495
Yuliya RuebVice President, Finance (PAO)11,258
Alan FuhrmanChief Financial Officer37,115
Bhavesh AsharChief Operating Officer15,013
Douglas J. WarnerChief Medical Officer25,000
Daniel BensenChief Discovery Officer146,981
Capital Healthcare Fund LP RADirector10,096,004
Rajeev M. ShahDirector8,477,275
Peter KolchinskyDirector9,909,154
RA Capital Nexus Fund, L.P.Director4,047,120
Ra Capital Management, L.P.Director10,259,291
Rehan VerjeeDirector972
Susan MoranDirector0
Adele M. GulfoDirector4,000
Jake SimsonDirector–
Stephen Michael RothenbergDirector0
Robert J. MoreDirector3,823,425
Habib J. DableDirector0
Gilla KaplanDirector28,231
Nina S. KjellsonDirector4,144,590

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payOtherTotalvs. prior year
Todd Harris
Chief Executive Officer
$658.00K$4.57M$325.71K$15.25K$5.57M-26%
Douglas Warner
Chief Medical Officer
$551.20K$1.61M$198.43K$15.05K$2.37M-50%
Bhavesh Ashar
Chief Operating Officer
$45.83K$4.64M–$1.02K$4.69M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Sep 15, 2021
Offer price
$16.00
Securities offered
10,800,000
Gross proceeds
$172.80M
Exchange
Nasdaq
Lock-up ends (est.)
Mar 14, 2022

“The initial public offering price per share is $16.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of February 25, 2026, we had 87 full-time employees, including a total of 21 employees with M.D.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?